| P50 | author | Adriano Arnobio | Q79563641 |
| P2093 | author name string | Roger A Levy | |
| | Vander Fernandes | |
| | Felipe Nogueira | |
| | João Luiz Pereira Vaz | |
| P2860 | cites work | Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study | Q24798468 |
| | Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment | Q24800888 |
| | Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey | Q24816756 |
| | Drug-induced lupus: an update on its dermatologic aspects | Q34611958 |
| | Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha | Q35555309 |
| | The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications | Q36373315 |
| | Systematic review of infliximab-induced autoantibodies and systemic lupus erythematosus. | Q38161813 |
| | Diagnosis and classification of drug-induced autoimmunity (DIA). | Q38181272 |
| | Drug-induced lupus: Including anti-tumour necrosis factor and interferon induced | Q38190033 |
| | Anti-chromatin and anti-histone antibodies in Egyptian patients with systemic lupus erythematosus | Q39448909 |
| | Autoimmune disease. a problem of defective apoptosis | Q40393793 |
| | Autoantibodies in patients with psoriatic arthritis on anti-TNFα therapy. | Q42787700 |
| | Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction. | Q44771208 |
| | Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers | Q46138857 |
| | Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis | Q49110928 |
| | Is the risk of tumour necrosis factor inhibitor-induced lupus or lupus-like syndrome the same with monoclonal antibodies and soluble receptor? A case/non-case study in a nationwide pharmacovigilance database. | Q51136025 |
| | [Antinuclear, anti-dsDNA and anti-ENA antibodies in patients affected with rheumatoid arthritis or ankylosing spondylitis during treatment with infliximab] | Q79865740 |
| | Infliximab treatment does not induce organ-specific or nonorgan-specific autoantibodies other than antinuclear and anti-double-stranded DNA autoantibodies in Crohn's disease | Q81381314 |
| | Infliximab-induced lupus-like reaction in a patient with psoriatic arthritis | Q81555183 |
| | Changes in chemokines and their receptors in blood during treatment with the TNF inhibitor infliximab in patients with rheumatoid arthritis | Q86052338 |
| | Drug-induced lupus | Q86441386 |
| P433 | issue | 2 | |
| P304 | page(s) | 325-332 | |
| P577 | publication date | 2015-12-17 | |
| P1433 | published in | Clinical Rheumatology | Q15754927 |
| P1476 | title | Infliximab-induced autoantibodies: a multicenter study | |
| P478 | volume | 35 | |